In the following video, Fool contributor Maxxwell Chatsko tells investors about pipeline developments fromÂ Merck . The Food and Drug Administration will review Biologics License Applications, or BLAs, for two investigational allergy tablets in the first half of 2014. Investors awaiting the next big pipeline hit to help replace falling revenue from patent expirations throughout the portfolio should have their ears perked up on the news.Â
How do these tablets work in the body? What is their revenue potential? Maxxwell explains just what it means for Merck and investors and answers one important question.
Can these products help Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.
Copyright © 2009 The Motley Fool, LLC. All rights reserved.